US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Niagen Bioscience

2.99

0.0000

Post-market: 2.990.00000.00%19:59 EDT

Volume:609.16K

Turnover:1.82M

Market Cap:238.14M

PE:15.72

High:3.03

Open:2.99

Low:2.97

Close:2.99

52wk High:10.52

52wk Low:2.87

Shares:79.64M

Float Shares:55.82M

Volume Ratio:1.63

T/O Rate:1.09%

Dividend:- -

Dividend Rate:- -

EPS(TTM):0.1901

EPS(LYR):0.2000

ROE:21.80%

ROA:5.44%

PB:2.89

PE(LYR):14.95

Loading ...

Overview Company News Filings

Niagen Bioscience: Expect Niagen Plus Growth & New Skincare Partnerships to Become Meaningful Contributors Beginning 2027

THOMSON REUTERS

Niagen Bioscience Inc Q2 Net Income USD 963 Thousand

THOMSON REUTERS

Niagen Bioscience Inc Q2 EPS USD 0.01 VS. Ibes Estimate USD 0.01

THOMSON REUTERS

Niagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results

THOMSON REUTERS

Niagen Bioscience Taps Evotec to Advance Preclinical Development of Nb4168 Rare-Disease Candidate

Niagen Bioscience - Plans Ind Application to FDA for Nb4168

THOMSON REUTERS

Niagen Bioscience Inc Expected to Post Earnings of 2 Cents a Share - Earnings Preview

Niagen Bioscience announces publication on muscle epigenetic age

Niagen Bioscience Reports Analysis Finds Niagen NR Cuts Muscle Epigenetic Age by About 2.5 Years in 5-month Trial

Niagen Bioscience (NAGE) Gets a Buy from Roth MKM

Niagen Bioscience CEO to Speak at Canaccord Genuity Growth Conference

Niagen Bioscience to Announce Second Quarter Financial Results on August 4

Niagen Bioscience Schedules Q2 Earnings Call After Market Close

Press Release: Niagen Bioscience to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026

Niagen Bioscience Names Abhijit Kale Senior Director of Global External Research

Niagen Bioscience Appoints Abhijit Kale, Ph.d., as Senior Director of Global External Research

THOMSON REUTERS

Niagen Bioscience's NB4168 Gets US FDA Rare Pediatric Disease Tag for Ataxia Telangiectasia

MT Newswires Live

Niagen Rises After U.S., EU Rare Disease Designations for Drug Candidate

Niagen Bioscience receives exclusive U.S. RPD, EMA OMPD for NB4168

Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (rpd) Designation and European Medicines Agency Orphan Medicinal Product Designation (ompd) for Nb4168 for the Treatment of Ataxia Telangiectasia (a-t)

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/stock/NAGE/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"NAGE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NAGE\",,,,,undefined,":{"symbol":"NAGE","market":"US","secType":"STK","nameCN":"Niagen Bioscience","latestPrice":2.99,"timestamp":1789761600000,"preClose":2.99,"halted":0,"volume":609162,"hourTrading":{"tag":"盘后","latestPrice":2.99,"preClose":2.99,"latestTime":"19:59 EDT","volume":48736,"amount":145720.4168,"timestamp":1789775964299,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0,"floatShares":55819168,"shares":79644327,"eps":0.190148,"marketStatus":"Market Closed","change":0,"latestTime":"09-18 16:00:00 EDT","open":2.99,"high":3.025,"low":2.9701,"amount":1823384.9995835999,"amplitude":0.018361,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.190148,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789977600000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":2.99,"preHourTrading":{"tag":"盘前","latestPrice":2.99,"preClose":2.99,"latestTime":"09:29 EDT","volume":300,"amount":897.0000000000001,"timestamp":1789738199910,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":2.99,"preClose":2.99,"latestTime":"19:59 EDT","volume":48736,"amount":145720.4168,"timestamp":1789775964299,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.6253365164721676,"impliedVol":1.2741,"impliedVolPercentile":0.5657},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NAGE\",,,,,undefined,":{"symbol":"NAGE","floatShares":55819168,"roa":"5.44%","roe":"21.80%","lyrEps":0.2,"volumeRatio":1.6253365164721676,"shares":79644327,"dividePrice":0,"high":3.025,"amplitude":0.018361,"preClose":2.99,"low":2.9701,"week52Low":2.87,"pbRate":"2.89","psRate":"1.84","week52High":10.52,"institutionHeld":0,"latestPrice":2.99,"eps":0.190148,"divideRate":0,"volume":609162,"delay":0,"ttmEps":0.190148,"open":2.99,"prevYearClose":6.36,"prevWeekClose":3.04,"prevMonthClose":3.13,"prevQuarterClose":3.19,"fiveDayClose":3.04,"twentyDayClose":3.15,"sixtyDayClose":3.45},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NAGE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-04","symbol":"NAGE","fiscalQuarterEnding":"2026/06","expectedEps":0.01,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1785816000000,"reportTimeType":"post","actualEps":0.01},{"market":"US","date":"2026-05-06","symbol":"NAGE","fiscalQuarterEnding":"2026/03","expectedEps":0.06,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778040000000,"reportTimeType":"post","actualEps":0.07},{"market":"US","date":"2026-03-04","symbol":"NAGE","fiscalQuarterEnding":"2025/12","expectedEps":0.02,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1772600400000,"reportTimeType":"post","actualEps":0.03},{"market":"US","date":"2025-11-04","symbol":"NAGE","fiscalQuarterEnding":"2025/09","expectedEps":0.02,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1762232400000,"reportTimeType":"post","actualEps":0.05},{"market":"US","date":"2025-08-06","symbol":"NAGE","fiscalQuarterEnding":"2025/06","expectedEps":0.02,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1754452800000,"reportTimeType":"post","actualEps":0.04}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NAGE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NAGE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.6667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":6,"updateTime":1783396800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NAGE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NAGE","date":"2026-09-18","current":15.724593,"percent":0.082667,"low":13.660897,"twenty":16.059048,"median":25.737197,"eighty":55.043436,"high":80.643552,"avg":34.607121,"sd":19.708691,"marketCap":237086075},"quantilePoints":[{"date":"2025-03-21","current":69.624479,"twenty":69.806742,"median":70.080136,"eighty":70.353531,"marketCap":595289295},{"date":"2025-03-28","current":67.346191,"twenty":68.676711,"median":69.624479,"eighty":70.371757,"marketCap":575809933},{"date":"2025-04-04","current":60.420196,"twenty":62.662031,"median":67.938546,"eighty":69.697384,"marketCap":516592673},{"date":"2025-04-11","current":51.67157,"twenty":54.861173,"median":62.880747,"eighty":69.551574,"marketCap":441791924},{"date":"2025-04-17","current":59.600012,"twenty":54.815607,"median":61.696037,"eighty":69.259953,"marketCap":509580103},{"date":"2025-04-25","current":67.255059,"twenty":55.043436,"median":62.151694,"eighty":68.530901,"marketCap":575030758},{"date":"2025-05-02","current":68.895427,"twenty":55.954751,"median":62.880747,"eighty":69.442216,"marketCap":589055899},{"date":"2025-05-09","current":51.710369,"twenty":55.954751,"median":65.022337,"eighty":70.535794,"marketCap":729374756},{"date":"2025-05-16","current":58.761783,"twenty":54.815607,"median":62.789615,"eighty":69.71561,"marketCap":828834951},{"date":"2025-05-23","current":56.859021,"twenty":55.043436,"median":61.650471,"eighty":69.624479,"marketCap":801996485},{"date":"2025-05-30","current":60.552618,"twenty":55.242319,"median":61.364091,"eighty":69.478669,"marketCap":854094682},{"date":"2025-06-06","current":64.414107,"twenty":55.822209,"median":61.604905,"eighty":69.296406,"marketCap":908560979},{"date":"2025-06-13","current":79.132535,"twenty":56.409541,"median":62.698483,"eighty":70.55402,"marketCap":1116164400},{"date":"2025-06-20","current":77.117845,"twenty":56.623974,"median":63.647427,"eighty":71.912091,"marketCap":1087747202},{"date":"2025-06-27","current":77.341699,"twenty":56.791865,"median":65.523561,"eighty":75.181504,"marketCap":1090904668},{"date":"2025-07-03","current":71.129739,"twenty":57.426855,"median":65.645306,"eighty":75.483707,"marketCap":1003284974},{"date":"2025-07-11","current":65.981088,"twenty":58.471876,"median":66.48476,"eighty":75.192697,"marketCap":930663244},{"date":"2025-07-18","current":57.950311,"twenty":58.471876,"median":65.645306,"eighty":75.114348,"marketCap":817389135},{"date":"2025-07-25","current":51.87826,"twenty":56.758286,"median":65.022337,"eighty":74.190401,"marketCap":731742856},{"date":"2025-08-01","current":52.325969,"twenty":55.224884,"median":64.358143,"eighty":72.732275,"marketCap":738057789},{"date":"2025-08-08","current":43.320593,"twenty":54.318273,"median":62.947882,"eighty":72.15947,"marketCap":768030786},{"date":"2025-08-15","current":43.771379,"twenty":53.985743,"median":62.607352,"eighty":71.628921,"marketCap":776022782},{"date":"2025-08-22","current":44.041851,"twenty":52.415511,"median":61.650471,"eighty":71.37484,"marketCap":780817979},{"date":"2025-08-29","current":44.267244,"twenty":51.68709,"median":61.280145,"eighty":71.129739,"marketCap":784813977},{"date":"2025-09-05","current":42.013311,"twenty":50.71606,"median":60.552618,"eighty":71.083855,"marketCap":744853999},{"date":"2025-09-12","current":43.365671,"twenty":45.745824,"median":60.318517,"eighty":70.845641,"marketCap":768829986},{"date":"2025-09-19","current":45.709762,"twenty":45.222912,"median":59.50888,"eighty":70.6087,"marketCap":810388363},{"date":"2025-09-26","current":42.419019,"twenty":45.024566,"median":58.520194,"eighty":70.371757,"marketCap":752046795},{"date":"2025-10-03","current":33.268051,"twenty":44.46559,"median":56.887002,"eighty":69.697384,"marketCap":589809282},{"date":"2025-10-10","current":34.079467,"twenty":44.02382,"median":56.607185,"eighty":69.623328,"marketCap":604194874},{"date":"2025-10-17","current":33.448366,"twenty":43.66319,"median":55.29204,"eighty":69.583421,"marketCap":593006080},{"date":"2025-10-24","current":33.448366,"twenty":43.41075,"median":54.929521,"eighty":69.405763,"marketCap":593006080},{"date":"2025-10-31","current":32.050928,"twenty":43.28453,"median":54.228731,"eighty":69.187048,"marketCap":568230894},{"date":"2025-11-07","current":25.87441,"twenty":42.455082,"median":54.050915,"eighty":68.822522,"marketCap":528588317},{"date":"2025-11-14","current":27.403352,"twenty":42.022327,"median":53.333314,"eighty":68.390298,"marketCap":559823081},{"date":"2025-11-21","current":26.30565,"twenty":34.151593,"median":52.437896,"eighty":67.731548,"marketCap":537398122},{"date":"2025-11-28","current":26.540872,"twenty":33.854074,"median":52.018169,"eighty":67.346191,"marketCap":542203471},{"date":"2025-12-05","current":26.266446,"twenty":33.628681,"median":51.67157,"eighty":67.255059,"marketCap":536597231},{"date":"2025-12-12","current":25.992021,"twenty":33.448366,"median":50.903505,"eighty":67.255059,"marketCap":530990991},{"date":"2025-12-19","current":25.482373,"twenty":32.772186,"median":49.393282,"eighty":66.988433,"marketCap":520579403},{"date":"2025-12-26","current":25.913613,"twenty":32.474667,"median":46.160548,"eighty":66.182557,"marketCap":529389208},{"date":"2026-01-02","current":24.933522,"twenty":30.002996,"median":45.709762,"eighty":65.94751,"marketCap":509366924},{"date":"2026-01-09","current":25.717595,"twenty":27.520963,"median":45.43929,"eighty":65.757233,"marketCap":525384751},{"date":"2026-01-16","current":24.737504,"twenty":27.019156,"median":45.168818,"eighty":65.594939,"marketCap":505362467},{"date":"2026-01-23","current":24.619893,"twenty":26.909386,"median":44.627874,"eighty":65.546241,"marketCap":502959792},{"date":"2026-01-30","current":23.482987,"twenty":26.540872,"median":44.492638,"eighty":65.122582,"marketCap":479733942},{"date":"2026-02-06","current":20.111473,"twenty":26.282128,"median":44.267244,"eighty":64.478311,"marketCap":410857283},{"date":"2026-02-13","current":19.954658,"twenty":25.944976,"median":44.008043,"eighty":64.391721,"marketCap":407653717},{"date":"2026-02-20","current":19.366604,"twenty":25.843047,"median":43.816458,"eighty":64.134289,"marketCap":395640346},{"date":"2026-02-27","current":20.307491,"twenty":25.623506,"median":43.591065,"eighty":63.1941,"marketCap":414861740},{"date":"2026-03-06","current":23.545172,"twenty":25.529418,"median":43.41075,"eighty":62.988163,"marketCap":409262188},{"date":"2026-03-13","current":22.252496,"twenty":25.411807,"median":43.320593,"eighty":62.862521,"marketCap":386792892},{"date":"2026-03-20","current":21.88316,"twenty":25.058974,"median":43.095199,"eighty":62.753162,"marketCap":380373093},{"date":"2026-03-27","current":20.636651,"twenty":24.761026,"median":42.599334,"eighty":62.487416,"marketCap":358706271},{"date":"2026-04-02","current":20.867486,"twenty":24.619893,"median":42.419019,"eighty":62.007672,"marketCap":362718645},{"date":"2026-04-10","current":20.682818,"twenty":24.345467,"median":42.035851,"eighty":61.696037,"marketCap":359508746},{"date":"2026-04-17","current":21.836993,"twenty":23.875024,"median":35.567063,"eighty":61.604905,"marketCap":379570618},{"date":"2026-04-24","current":21.836993,"twenty":23.545172,"median":34.102007,"eighty":61.448036,"marketCap":379570618},{"date":"2026-05-01","current":21.836993,"twenty":23.175836,"median":33.854074,"eighty":61.280145,"marketCap":379570618},{"date":"2026-05-08","current":18.041368,"twenty":22.760333,"median":33.696298,"eighty":61.168218,"marketCap":336236974},{"date":"2026-05-15","current":16.273169,"twenty":22.34483,"median":33.493445,"eighty":60.552618,"marketCap":303283042},{"date":"2026-05-22","current":16.230344,"twenty":22.248072,"median":33.448366,"eighty":60.552618,"marketCap":302484929},{"date":"2026-05-29","current":16.444465,"twenty":22.012428,"median":33.155355,"eighty":60.44668,"marketCap":306475495},{"date":"2026-06-05","current":14.988445,"twenty":21.873927,"median":32.772186,"eighty":60.257509,"marketCap":279339644},{"date":"2026-06-12","current":14.688676,"twenty":21.735571,"median":32.546792,"eighty":59.723377,"marketCap":273752851},{"date":"2026-06-18","current":14.431731,"twenty":21.468256,"median":32.208703,"eighty":59.545333,"marketCap":268964171},{"date":"2026-06-26","current":14.174786,"twenty":20.98752,"median":28.148222,"eighty":59.396403,"marketCap":264175492},{"date":"2026-07-02","current":14.260435,"twenty":20.867486,"median":27.834592,"eighty":59.097565,"marketCap":265771718},{"date":"2026-07-10","current":14.945621,"twenty":20.636651,"median":27.324945,"eighty":58.568512,"marketCap":278541531},{"date":"2026-07-17","current":14.560203,"twenty":20.370149,"median":27.050519,"eighty":58.147287,"marketCap":271358511},{"date":"2026-07-24","current":13.660897,"twenty":20.127155,"median":26.95251,"eighty":57.524987,"marketCap":254598133},{"date":"2026-07-31","current":14.21761,"twenty":20.033066,"median":26.893705,"eighty":56.881406,"marketCap":264973605},{"date":"2026-08-07","current":15.07415,"twenty":19.767151,"median":26.540872,"eighty":56.825443,"marketCap":241050726},{"date":"2026-08-14","current":15.123736,"twenty":19.424638,"median":26.403659,"eighty":56.657552,"marketCap":241843656},{"date":"2026-08-21","current":15.619596,"twenty":18.243689,"median":26.266446,"eighty":56.409541,"marketCap":249772956},{"date":"2026-08-28","current":15.917112,"twenty":16.632891,"median":26.011623,"eighty":55.822209,"marketCap":254530536},{"date":"2026-09-04","current":15.421252,"twenty":16.410206,"median":25.913613,"eighty":55.269655,"marketCap":246601236},{"date":"2026-09-11","current":15.049357,"twenty":16.273169,"median":25.835206,"eighty":55.180113,"marketCap":240654261},{"date":"2026-09-18","current":14.826219,"twenty":16.059048,"median":25.737197,"eighty":55.043436,"marketCap":237086075}],"updateTime":1789914801045},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NAGE\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2657619355","title":"Niagen Bioscience: Expect Niagen Plus Growth & New Skincare Partnerships to Become Meaningful Contributors Beginning 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2657619355","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657619355?lang=en_us&edition=fundamental","pubTime":"2026-08-05 04:02","pubTimestamp":1785873721,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nPLXTMZR6V:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NAGE","BK4183","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657569864","title":"Niagen Bioscience Inc Q2 Net Income USD 963 Thousand","url":"https://stock-news.laohu8.com/highlight/detail?id=2657569864","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657569864?lang=en_us&edition=fundamental","pubTime":"2026-08-05 04:02","pubTimestamp":1785873721,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nPLXTMZR6V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4183","NAGE","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657028569","title":"Niagen Bioscience Inc Q2 EPS USD 0.01 VS. Ibes Estimate USD 0.01","url":"https://stock-news.laohu8.com/highlight/detail?id=2657028569","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657028569?lang=en_us&edition=fundamental","pubTime":"2026-08-05 04:02","pubTimestamp":1785873721,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nPLXTMZR6V:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NAGE","BK4183","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657698875","title":"Niagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2657698875","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657698875?lang=en_us&edition=fundamental","pubTime":"2026-08-05 04:02","pubTimestamp":1785873720,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nTUA42RMYR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4183","BK4121","NAGE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656794493","title":"Niagen Bioscience Taps Evotec to Advance Preclinical Development of Nb4168 Rare-Disease Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2656794493","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656794493?lang=en_us&edition=fundamental","pubTime":"2026-08-03 20:33","pubTimestamp":1785760393,"startTime":"0","endTime":"0","summary":"Niagen Bioscience taps Evotec to advance preclinical development of NB4168 rare-disease candidateNiagen Bioscience selected Evotec as a contract research partner to advance preclinical development of ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nNDL4wjyhJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NAGE","BK4183","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656379108","title":"Niagen Bioscience - Plans Ind Application to FDA for Nb4168","url":"https://stock-news.laohu8.com/highlight/detail?id=2656379108","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656379108?lang=en_us&edition=fundamental","pubTime":"2026-08-03 20:33","pubTimestamp":1785760382,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nFWN44019B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4121","BK4183","NAGE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656734391","title":"Niagen Bioscience Inc Expected to Post Earnings of 2 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2656734391","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656734391?lang=en_us&edition=fundamental","pubTime":"2026-08-01 05:11","pubTimestamp":1785532266,"startTime":"0","endTime":"0","summary":"Niagen Bioscience Inc <NAGE.OQ> expected to post earnings of2cents a share - Earnings PreviewNiagen Bioscience IncNAGE.OQNAGE.Ois expected to  show a fall in quarterly revenue when it reports  results","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nL8N43X3AR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","BK4121","NAGE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654002023","title":"Niagen Bioscience announces publication on muscle epigenetic age","url":"https://stock-news.laohu8.com/highlight/detail?id=2654002023","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654002023?lang=en_us&edition=fundamental","pubTime":"2026-07-28 20:41","pubTimestamp":1785242484,"startTime":"0","endTime":"0","summary":"Niagen Bioscience (NAGE) announced the publication of a new peer-reviewed analysis of past clinical studies in Aging Cell examining the effects of ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/niagen-bioscience-announces-publication-on-muscle-epigenetic-age-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/niagen-bioscience-announces-publication-on-muscle-epigenetic-age-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NAGE","BK4183","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654004720","title":"Niagen Bioscience Reports Analysis Finds Niagen NR Cuts Muscle Epigenetic Age by About 2.5 Years in 5-month Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2654004720","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654004720?lang=en_us&edition=fundamental","pubTime":"2026-07-28 20:32","pubTimestamp":1785241943,"startTime":"0","endTime":"0","summary":"Niagen Bioscience reports analysis finds Niagen NR cuts muscle epigenetic age by about 2.5 years in 5-month trialNiagen Bioscience flagged a newly published peer-reviewed analysis in Aging Cell re-exa","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nNDL27jx7V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","NAGE","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654498260","title":"Niagen Bioscience (NAGE) Gets a Buy from Roth MKM","url":"https://stock-news.laohu8.com/highlight/detail?id=2654498260","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654498260?lang=en_us&edition=fundamental","pubTime":"2026-07-27 22:45","pubTimestamp":1785163533,"startTime":"0","endTime":"0","summary":"In a report released today, Sean McGowan from Roth MKM maintained a Buy rating on Niagen Bioscience, with a price target of $12.00. According to Ti...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/niagen-bioscience-nage-gets-a-buy-from-roth-mkm-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/niagen-bioscience-nage-gets-a-buy-from-roth-mkm-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4121","NAGE","BK4183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654127010","title":"Niagen Bioscience CEO to Speak at Canaccord Genuity Growth Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2654127010","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654127010?lang=en_us&edition=fundamental","pubTime":"2026-07-27 20:33","pubTimestamp":1785155614,"startTime":"0","endTime":"0","summary":"Niagen Bioscience CEO to speak at Canaccord Genuity Growth ConferenceNiagen Bioscience executives will attend Canaccord Genuity’s 46th Annual Growth Conference in Boston on Aug. 11-13, 2026.CEO Rob Fr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nNDL4Ch5Gj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","BK4183","NAGE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130239342","title":"Niagen Bioscience to Announce Second Quarter Financial Results on August 4","url":"https://stock-news.laohu8.com/highlight/detail?id=1130239342","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1130239342?lang=en_us&edition=fundamental","pubTime":"2026-07-21 21:51","pubTimestamp":1784641890,"startTime":"0","endTime":"0","summary":"Biotechnology company Niagen Bioscience (Nasdaq: NAGE), which focuses on NAD+ science and healthy aging, has announced it will release its second quarter financial results after the U.S. market...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SQMX","BK4183","NAGE","PSET","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653277476","title":"Niagen Bioscience Schedules Q2 Earnings Call After Market Close","url":"https://stock-news.laohu8.com/highlight/detail?id=2653277476","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653277476?lang=en_us&edition=fundamental","pubTime":"2026-07-21 20:32","pubTimestamp":1784637143,"startTime":"0","endTime":"0","summary":"Niagen Bioscience schedules Q2 earnings call after market closeNiagen Bioscience schedules Q2 2026 results release for Tuesday, Aug. 4, 2026.Earnings conference call, Tuesday, Aug. 4, 2026 at 4:30 p.m","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260721:nNDL7nG84j:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","BK4183","NAGE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653277253","title":"Press Release: Niagen Bioscience to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2653277253","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653277253?lang=en_us&edition=fundamental","pubTime":"2026-07-21 20:32","pubTimestamp":1784637120,"startTime":"0","endTime":"0","summary":"LOS ANGELES--(BUSINESS WIRE)--July 21, 2026--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, toda","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","BK4588","BK4604","BK4232","BK4585","BK4121","BK4183","BK4099","BK4555","R","03160","NAGE","TM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651544413","title":"Niagen Bioscience Names Abhijit Kale Senior Director of Global External Research","url":"https://stock-news.laohu8.com/highlight/detail?id=2651544413","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651544413?lang=en_us&edition=fundamental","pubTime":"2026-07-16 20:37","pubTimestamp":1784205423,"startTime":"0","endTime":"0","summary":"Niagen Bioscience names Abhijit Kale senior director of global external researchNiagen Bioscience named Abhijit Kale as senior director of global external research, effective July 20, 2026.Kale will r","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260716:nNDLccw2SH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","BK4121","NAGE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651444642","title":"Niagen Bioscience Appoints Abhijit Kale, Ph.d., as Senior Director of Global External Research","url":"https://stock-news.laohu8.com/highlight/detail?id=2651444642","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651444642?lang=en_us&edition=fundamental","pubTime":"2026-07-16 20:32","pubTimestamp":1784205120,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260716:nTUA8CQYTY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4121","BK4183","NAGE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651114994","title":"Niagen Bioscience's NB4168 Gets US FDA Rare Pediatric Disease Tag for Ataxia Telangiectasia","url":"https://stock-news.laohu8.com/highlight/detail?id=2651114994","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651114994?lang=en_us&edition=fundamental","pubTime":"2026-07-13 21:04","pubTimestamp":1783947847,"startTime":"0","endTime":"0","summary":"Niagen Bioscience  has received rare pediatric disease designation from the US Food and Drug Administration for NB4168 in treating ataxia telangiectasia, a multisystem disorder, the company said Monday.The European Medicines Agency also granted Orphan Medicinal Product Designation to NB4168 for the same indication, the company said.The regulatory designations provide incentives to support the drug's development for the rare disease, the company added.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NAGE","BK4588","LABU","BK4183","BK4585","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651111777","title":"Niagen Rises After U.S., EU Rare Disease Designations for Drug Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2651111777","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651111777?lang=en_us&edition=fundamental","pubTime":"2026-07-13 20:49","pubTimestamp":1783946985,"startTime":"0","endTime":"0","summary":"BUZZ-Niagen rises after U.S., EU rare disease designations for drug candidate** Shares of biotech firm Niagen BioscienceNAGE.Orise 2.6% to $3.47 premarket** Co says its experimental drug, NB4168, rece","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nL4N43F12L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","BK4183","NAGE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651111259","title":"Niagen Bioscience receives exclusive U.S. RPD, EMA OMPD for NB4168","url":"https://stock-news.laohu8.com/highlight/detail?id=2651111259","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651111259?lang=en_us&edition=fundamental","pubTime":"2026-07-13 20:35","pubTimestamp":1783946107,"startTime":"0","endTime":"0","summary":"Niagen Bioscience (NAGE) announced that the U.S. Food & Drug Administration, FDA, granted Rare Pediatric Disease, RPD, Designation for its propriet...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/niagen-bioscience-receives-exclusive-u-s-rpd-ema-ompd-for-nb4168-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/niagen-bioscience-receives-exclusive-u-s-rpd-ema-ompd-for-nb4168-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1878469433.USD","RPD","BK4081","BK4588","EMA","NAGE","BK4585","BK4183","BK4097","BK4121","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651111606","title":"Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (rpd) Designation and European Medicines Agency Orphan Medicinal Product Designation (ompd) for Nb4168 for the Treatment of Ataxia Telangiectasia (a-t)","url":"https://stock-news.laohu8.com/highlight/detail?id=2651111606","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651111606?lang=en_us&edition=fundamental","pubTime":"2026-07-13 20:32","pubTimestamp":1783945920,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nTUA13G7ZY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NAGE","BK4121","BK4183"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":2,"totalSize":94,"code":"91000000","status":"200"}]}}